nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—HIF1A—pancreatic cancer	0.341	0.713	CbGaD
Carvedilol—VEGFA—pancreatic cancer	0.137	0.287	CbGaD
Carvedilol—XDH—Doxorubicin—pancreatic cancer	0.0286	0.108	CbGbCtD
Carvedilol—CYP1A1—Dacarbazine—pancreatic cancer	0.025	0.0941	CbGbCtD
Carvedilol—CYP1A1—Tamoxifen—pancreatic cancer	0.0199	0.0749	CbGbCtD
Carvedilol—CYP2E1—Dacarbazine—pancreatic cancer	0.0193	0.0727	CbGbCtD
Carvedilol—KCNH2—Sunitinib—pancreatic cancer	0.0174	0.0656	CbGbCtD
Carvedilol—CYP1A1—Erlotinib—pancreatic cancer	0.0169	0.0637	CbGbCtD
Carvedilol—CYP2E1—Tamoxifen—pancreatic cancer	0.0154	0.0578	CbGbCtD
Carvedilol—CYP1A2—Dacarbazine—pancreatic cancer	0.0112	0.0421	CbGbCtD
Carvedilol—CYP1A2—Tamoxifen—pancreatic cancer	0.00888	0.0335	CbGbCtD
Carvedilol—CYP2C9—Tamoxifen—pancreatic cancer	0.008	0.0301	CbGbCtD
Carvedilol—ABCB1—Tamoxifen—pancreatic cancer	0.00776	0.0293	CbGbCtD
Carvedilol—CYP1A2—Erlotinib—pancreatic cancer	0.00755	0.0284	CbGbCtD
Carvedilol—CYP2D6—Tamoxifen—pancreatic cancer	0.00732	0.0276	CbGbCtD
Carvedilol—SELE—umbilical vein—pancreatic cancer	0.0068	0.186	CbGeAlD
Carvedilol—ABCB1—Gemcitabine—pancreatic cancer	0.00669	0.0252	CbGbCtD
Carvedilol—ABCB1—Erlotinib—pancreatic cancer	0.0066	0.0249	CbGbCtD
Carvedilol—CYP1A2—Fluorouracil—pancreatic cancer	0.00654	0.0247	CbGbCtD
Carvedilol—VCAM1—umbilical vein—pancreatic cancer	0.00626	0.171	CbGeAlD
Carvedilol—CYP2D6—Erlotinib—pancreatic cancer	0.00622	0.0234	CbGbCtD
Carvedilol—ABCB1—Irinotecan—pancreatic cancer	0.00596	0.0225	CbGbCtD
Carvedilol—CYP2C9—Fluorouracil—pancreatic cancer	0.0059	0.0222	CbGbCtD
Carvedilol—CYP3A4—Tamoxifen—pancreatic cancer	0.00465	0.0175	CbGbCtD
Carvedilol—ABCB1—Docetaxel—pancreatic cancer	0.00437	0.0165	CbGbCtD
Carvedilol—ABCB1—Sunitinib—pancreatic cancer	0.00435	0.0164	CbGbCtD
Carvedilol—CYP3A4—Erlotinib—pancreatic cancer	0.00396	0.0149	CbGbCtD
Carvedilol—CYP3A4—Irinotecan—pancreatic cancer	0.00357	0.0135	CbGbCtD
Carvedilol—ABCB1—Doxorubicin—pancreatic cancer	0.00326	0.0123	CbGbCtD
Carvedilol—CYP2D6—Doxorubicin—pancreatic cancer	0.00307	0.0116	CbGbCtD
Carvedilol—CYP3A4—Docetaxel—pancreatic cancer	0.00262	0.00986	CbGbCtD
Carvedilol—CYP3A4—Sunitinib—pancreatic cancer	0.00261	0.00982	CbGbCtD
Carvedilol—HIF1A—gall bladder—pancreatic cancer	0.00248	0.0676	CbGeAlD
Carvedilol—CYP3A4—Doxorubicin—pancreatic cancer	0.00195	0.00735	CbGbCtD
Carvedilol—NPPB—pancreas—pancreatic cancer	0.00191	0.0521	CbGeAlD
Carvedilol—VCAM1—islet of Langerhans—pancreatic cancer	0.00169	0.046	CbGeAlD
Carvedilol—HIF1A—islet of Langerhans—pancreatic cancer	0.00162	0.0443	CbGeAlD
Carvedilol—GJA1—islet of Langerhans—pancreatic cancer	0.00157	0.043	CbGeAlD
Carvedilol—VEGFA—islet of Langerhans—pancreatic cancer	0.00124	0.0339	CbGeAlD
Carvedilol—VCAM1—pancreas—pancreatic cancer	0.00119	0.0324	CbGeAlD
Carvedilol—HIF1A—pancreas—pancreatic cancer	0.00114	0.0311	CbGeAlD
Carvedilol—GJA1—pancreas—pancreatic cancer	0.00111	0.0302	CbGeAlD
Carvedilol—SELE—digestive system—pancreatic cancer	0.0011	0.03	CbGeAlD
Carvedilol—VCAM1—digestive system—pancreatic cancer	0.00101	0.0276	CbGeAlD
Carvedilol—HIF1A—digestive system—pancreatic cancer	0.000974	0.0266	CbGeAlD
Carvedilol—GJA1—digestive system—pancreatic cancer	0.000945	0.0258	CbGeAlD
Carvedilol—VEGFA—pancreas—pancreatic cancer	0.000874	0.0239	CbGeAlD
Carvedilol—NDUFC2—digestive system—pancreatic cancer	0.000823	0.0225	CbGeAlD
Carvedilol—XDH—digestive system—pancreatic cancer	0.000664	0.0181	CbGeAlD
Carvedilol—KCNH2—islet of Langerhans—pancreatic cancer	0.00045	0.0123	CbGeAlD
Carvedilol—ADRA2A—islet of Langerhans—pancreatic cancer	0.000355	0.00968	CbGeAlD
Carvedilol—ADRA2C—pancreas—pancreatic cancer	0.000312	0.00853	CbGeAlD
Carvedilol—ADRA2A—pancreas—pancreatic cancer	0.000249	0.0068	CbGeAlD
Carvedilol—CYP1A2—digestive system—pancreatic cancer	0.000232	0.00632	CbGeAlD
Carvedilol—CYP1A1—digestive system—pancreatic cancer	0.000228	0.00623	CbGeAlD
Carvedilol—CYP2C9—digestive system—pancreatic cancer	0.00022	0.006	CbGeAlD
Carvedilol—CYP2E1—digestive system—pancreatic cancer	0.000208	0.00569	CbGeAlD
Carvedilol—PTGS1—digestive system—pancreatic cancer	0.000201	0.00548	CbGeAlD
Carvedilol—ABCB1—islet of Langerhans—pancreatic cancer	0.000198	0.00539	CbGeAlD
Carvedilol—CYP3A4—digestive system—pancreatic cancer	0.000168	0.00457	CbGeAlD
Carvedilol—CYP2D6—digestive system—pancreatic cancer	0.000165	0.0045	CbGeAlD
Carvedilol—ABCB1—pancreas—pancreatic cancer	0.000139	0.00379	CbGeAlD
Carvedilol—ABCB1—digestive system—pancreatic cancer	0.000119	0.00324	CbGeAlD
Carvedilol—Photosensitivity reaction—Epirubicin—pancreatic cancer	6.12e-05	0.000555	CcSEcCtD
Carvedilol—Weight increased—Epirubicin—pancreatic cancer	6.1e-05	0.000554	CcSEcCtD
Carvedilol—Loss of consciousness—Docetaxel—pancreatic cancer	6.09e-05	0.000552	CcSEcCtD
Carvedilol—Weight decreased—Epirubicin—pancreatic cancer	6.06e-05	0.000551	CcSEcCtD
Carvedilol—Hyperglycaemia—Epirubicin—pancreatic cancer	6.05e-05	0.000549	CcSEcCtD
Carvedilol—Cough—Docetaxel—pancreatic cancer	6.04e-05	0.000549	CcSEcCtD
Carvedilol—Angina pectoris—Doxorubicin—pancreatic cancer	6.04e-05	0.000548	CcSEcCtD
Carvedilol—Hypersensitivity—Irinotecan—pancreatic cancer	6.02e-05	0.000547	CcSEcCtD
Carvedilol—Pneumonia—Epirubicin—pancreatic cancer	6.01e-05	0.000546	CcSEcCtD
Carvedilol—Convulsion—Docetaxel—pancreatic cancer	6e-05	0.000545	CcSEcCtD
Carvedilol—Hypertension—Docetaxel—pancreatic cancer	5.98e-05	0.000543	CcSEcCtD
Carvedilol—Bronchitis—Doxorubicin—pancreatic cancer	5.96e-05	0.000541	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	5.92e-05	0.000538	CcSEcCtD
Carvedilol—Chest pain—Docetaxel—pancreatic cancer	5.89e-05	0.000535	CcSEcCtD
Carvedilol—Myalgia—Docetaxel—pancreatic cancer	5.89e-05	0.000535	CcSEcCtD
Carvedilol—Arthralgia—Docetaxel—pancreatic cancer	5.89e-05	0.000535	CcSEcCtD
Carvedilol—Nausea—Sunitinib—pancreatic cancer	5.89e-05	0.000535	CcSEcCtD
Carvedilol—Pancytopenia—Doxorubicin—pancreatic cancer	5.89e-05	0.000535	CcSEcCtD
Carvedilol—Renal failure—Epirubicin—pancreatic cancer	5.87e-05	0.000533	CcSEcCtD
Carvedilol—Asthenia—Irinotecan—pancreatic cancer	5.86e-05	0.000532	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	5.85e-05	0.000531	CcSEcCtD
Carvedilol—Urinary tract infection—Epirubicin—pancreatic cancer	5.81e-05	0.000527	CcSEcCtD
Carvedilol—Hypersensitivity—Fluorouracil—pancreatic cancer	5.77e-05	0.000524	CcSEcCtD
Carvedilol—Dry mouth—Docetaxel—pancreatic cancer	5.76e-05	0.000523	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	5.76e-05	0.000523	CcSEcCtD
Carvedilol—Pollakiuria—Doxorubicin—pancreatic cancer	5.73e-05	0.00052	CcSEcCtD
Carvedilol—Asthenia—Gemcitabine—pancreatic cancer	5.71e-05	0.000519	CcSEcCtD
Carvedilol—Haematuria—Epirubicin—pancreatic cancer	5.7e-05	0.000517	CcSEcCtD
Carvedilol—Confusional state—Docetaxel—pancreatic cancer	5.7e-05	0.000517	CcSEcCtD
Carvedilol—Photosensitivity reaction—Doxorubicin—pancreatic cancer	5.66e-05	0.000514	CcSEcCtD
Carvedilol—Oedema—Docetaxel—pancreatic cancer	5.65e-05	0.000513	CcSEcCtD
Carvedilol—Anaphylactic shock—Docetaxel—pancreatic cancer	5.65e-05	0.000513	CcSEcCtD
Carvedilol—Weight increased—Doxorubicin—pancreatic cancer	5.64e-05	0.000512	CcSEcCtD
Carvedilol—Pruritus—Gemcitabine—pancreatic cancer	5.63e-05	0.000511	CcSEcCtD
Carvedilol—Infection—Docetaxel—pancreatic cancer	5.61e-05	0.00051	CcSEcCtD
Carvedilol—Weight decreased—Doxorubicin—pancreatic cancer	5.61e-05	0.000509	CcSEcCtD
Carvedilol—Sinusitis—Epirubicin—pancreatic cancer	5.61e-05	0.000509	CcSEcCtD
Carvedilol—Hyperglycaemia—Doxorubicin—pancreatic cancer	5.59e-05	0.000508	CcSEcCtD
Carvedilol—Diarrhoea—Irinotecan—pancreatic cancer	5.59e-05	0.000508	CcSEcCtD
Carvedilol—Pneumonia—Doxorubicin—pancreatic cancer	5.56e-05	0.000505	CcSEcCtD
Carvedilol—Shock—Docetaxel—pancreatic cancer	5.56e-05	0.000505	CcSEcCtD
Carvedilol—Pruritus—Fluorouracil—pancreatic cancer	5.54e-05	0.000503	CcSEcCtD
Carvedilol—Thrombocytopenia—Docetaxel—pancreatic cancer	5.53e-05	0.000502	CcSEcCtD
Carvedilol—Tachycardia—Docetaxel—pancreatic cancer	5.51e-05	0.000501	CcSEcCtD
Carvedilol—Skin disorder—Docetaxel—pancreatic cancer	5.49e-05	0.000498	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	5.48e-05	0.000498	CcSEcCtD
Carvedilol—Bradycardia—Epirubicin—pancreatic cancer	5.46e-05	0.000496	CcSEcCtD
Carvedilol—Diarrhoea—Gemcitabine—pancreatic cancer	5.45e-05	0.000495	CcSEcCtD
Carvedilol—Renal failure—Doxorubicin—pancreatic cancer	5.44e-05	0.000493	CcSEcCtD
Carvedilol—Dizziness—Irinotecan—pancreatic cancer	5.41e-05	0.000491	CcSEcCtD
Carvedilol—Haemoglobin—Epirubicin—pancreatic cancer	5.39e-05	0.00049	CcSEcCtD
Carvedilol—Anorexia—Docetaxel—pancreatic cancer	5.39e-05	0.000489	CcSEcCtD
Carvedilol—Rhinitis—Epirubicin—pancreatic cancer	5.38e-05	0.000488	CcSEcCtD
Carvedilol—Urinary tract infection—Doxorubicin—pancreatic cancer	5.37e-05	0.000488	CcSEcCtD
Carvedilol—Haemorrhage—Epirubicin—pancreatic cancer	5.36e-05	0.000487	CcSEcCtD
Carvedilol—Diarrhoea—Fluorouracil—pancreatic cancer	5.36e-05	0.000486	CcSEcCtD
Carvedilol—Hypoaesthesia—Epirubicin—pancreatic cancer	5.34e-05	0.000485	CcSEcCtD
Carvedilol—Pharyngitis—Epirubicin—pancreatic cancer	5.32e-05	0.000483	CcSEcCtD
Carvedilol—Urinary tract disorder—Epirubicin—pancreatic cancer	5.3e-05	0.000481	CcSEcCtD
Carvedilol—Oedema peripheral—Epirubicin—pancreatic cancer	5.28e-05	0.00048	CcSEcCtD
Carvedilol—Hypotension—Docetaxel—pancreatic cancer	5.28e-05	0.000479	CcSEcCtD
Carvedilol—Haematuria—Doxorubicin—pancreatic cancer	5.27e-05	0.000479	CcSEcCtD
Carvedilol—Urethral disorder—Epirubicin—pancreatic cancer	5.26e-05	0.000477	CcSEcCtD
Carvedilol—Vomiting—Irinotecan—pancreatic cancer	5.2e-05	0.000472	CcSEcCtD
Carvedilol—Sinusitis—Doxorubicin—pancreatic cancer	5.19e-05	0.000471	CcSEcCtD
Carvedilol—Dizziness—Fluorouracil—pancreatic cancer	5.18e-05	0.00047	CcSEcCtD
Carvedilol—Visual impairment—Epirubicin—pancreatic cancer	5.17e-05	0.000469	CcSEcCtD
Carvedilol—Rash—Irinotecan—pancreatic cancer	5.15e-05	0.000468	CcSEcCtD
Carvedilol—Dermatitis—Irinotecan—pancreatic cancer	5.15e-05	0.000467	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	5.15e-05	0.000467	CcSEcCtD
Carvedilol—Headache—Irinotecan—pancreatic cancer	5.12e-05	0.000465	CcSEcCtD
Carvedilol—Insomnia—Docetaxel—pancreatic cancer	5.11e-05	0.000464	CcSEcCtD
Carvedilol—Paraesthesia—Docetaxel—pancreatic cancer	5.07e-05	0.000461	CcSEcCtD
Carvedilol—Erythema multiforme—Epirubicin—pancreatic cancer	5.07e-05	0.000461	CcSEcCtD
Carvedilol—Vomiting—Gemcitabine—pancreatic cancer	5.06e-05	0.00046	CcSEcCtD
Carvedilol—Bradycardia—Doxorubicin—pancreatic cancer	5.05e-05	0.000459	CcSEcCtD
Carvedilol—Dyspnoea—Docetaxel—pancreatic cancer	5.04e-05	0.000457	CcSEcCtD
Carvedilol—Somnolence—Docetaxel—pancreatic cancer	5.02e-05	0.000456	CcSEcCtD
Carvedilol—Rash—Gemcitabine—pancreatic cancer	5.02e-05	0.000456	CcSEcCtD
Carvedilol—Dermatitis—Gemcitabine—pancreatic cancer	5.02e-05	0.000455	CcSEcCtD
Carvedilol—Tinnitus—Epirubicin—pancreatic cancer	5e-05	0.000454	CcSEcCtD
Carvedilol—Haemoglobin—Doxorubicin—pancreatic cancer	4.99e-05	0.000453	CcSEcCtD
Carvedilol—Headache—Gemcitabine—pancreatic cancer	4.99e-05	0.000453	CcSEcCtD
Carvedilol—Vomiting—Fluorouracil—pancreatic cancer	4.98e-05	0.000452	CcSEcCtD
Carvedilol—Rhinitis—Doxorubicin—pancreatic cancer	4.98e-05	0.000452	CcSEcCtD
Carvedilol—Dyspepsia—Docetaxel—pancreatic cancer	4.97e-05	0.000452	CcSEcCtD
Carvedilol—Haemorrhage—Doxorubicin—pancreatic cancer	4.96e-05	0.000451	CcSEcCtD
Carvedilol—Hypoaesthesia—Doxorubicin—pancreatic cancer	4.94e-05	0.000448	CcSEcCtD
Carvedilol—Rash—Fluorouracil—pancreatic cancer	4.94e-05	0.000448	CcSEcCtD
Carvedilol—Dermatitis—Fluorouracil—pancreatic cancer	4.93e-05	0.000448	CcSEcCtD
Carvedilol—Pharyngitis—Doxorubicin—pancreatic cancer	4.93e-05	0.000447	CcSEcCtD
Carvedilol—Decreased appetite—Docetaxel—pancreatic cancer	4.91e-05	0.000446	CcSEcCtD
Carvedilol—Headache—Fluorouracil—pancreatic cancer	4.9e-05	0.000445	CcSEcCtD
Carvedilol—Urinary tract disorder—Doxorubicin—pancreatic cancer	4.9e-05	0.000445	CcSEcCtD
Carvedilol—Oedema peripheral—Doxorubicin—pancreatic cancer	4.89e-05	0.000444	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Docetaxel—pancreatic cancer	4.88e-05	0.000443	CcSEcCtD
Carvedilol—Fatigue—Docetaxel—pancreatic cancer	4.87e-05	0.000442	CcSEcCtD
Carvedilol—Angiopathy—Epirubicin—pancreatic cancer	4.87e-05	0.000442	CcSEcCtD
Carvedilol—Urethral disorder—Doxorubicin—pancreatic cancer	4.87e-05	0.000442	CcSEcCtD
Carvedilol—Nausea—Irinotecan—pancreatic cancer	4.86e-05	0.000441	CcSEcCtD
Carvedilol—Immune system disorder—Epirubicin—pancreatic cancer	4.85e-05	0.00044	CcSEcCtD
Carvedilol—Mediastinal disorder—Epirubicin—pancreatic cancer	4.83e-05	0.000439	CcSEcCtD
Carvedilol—Pain—Docetaxel—pancreatic cancer	4.83e-05	0.000439	CcSEcCtD
Carvedilol—Constipation—Docetaxel—pancreatic cancer	4.83e-05	0.000439	CcSEcCtD
Carvedilol—Visual impairment—Doxorubicin—pancreatic cancer	4.78e-05	0.000434	CcSEcCtD
Carvedilol—Alopecia—Epirubicin—pancreatic cancer	4.74e-05	0.00043	CcSEcCtD
Carvedilol—Nausea—Gemcitabine—pancreatic cancer	4.73e-05	0.000429	CcSEcCtD
Carvedilol—Erythema multiforme—Doxorubicin—pancreatic cancer	4.69e-05	0.000426	CcSEcCtD
Carvedilol—Malnutrition—Epirubicin—pancreatic cancer	4.67e-05	0.000424	CcSEcCtD
Carvedilol—Feeling abnormal—Docetaxel—pancreatic cancer	4.66e-05	0.000423	CcSEcCtD
Carvedilol—Nausea—Fluorouracil—pancreatic cancer	4.65e-05	0.000422	CcSEcCtD
Carvedilol—Tinnitus—Doxorubicin—pancreatic cancer	4.63e-05	0.00042	CcSEcCtD
Carvedilol—Gastrointestinal pain—Docetaxel—pancreatic cancer	4.62e-05	0.00042	CcSEcCtD
Carvedilol—Flatulence—Epirubicin—pancreatic cancer	4.6e-05	0.000418	CcSEcCtD
Carvedilol—Tension—Epirubicin—pancreatic cancer	4.58e-05	0.000416	CcSEcCtD
Carvedilol—Nervousness—Epirubicin—pancreatic cancer	4.54e-05	0.000412	CcSEcCtD
Carvedilol—Back pain—Epirubicin—pancreatic cancer	4.52e-05	0.00041	CcSEcCtD
Carvedilol—Angiopathy—Doxorubicin—pancreatic cancer	4.5e-05	0.000409	CcSEcCtD
Carvedilol—Muscle spasms—Epirubicin—pancreatic cancer	4.49e-05	0.000408	CcSEcCtD
Carvedilol—Immune system disorder—Doxorubicin—pancreatic cancer	4.48e-05	0.000407	CcSEcCtD
Carvedilol—Mediastinal disorder—Doxorubicin—pancreatic cancer	4.47e-05	0.000406	CcSEcCtD
Carvedilol—Abdominal pain—Docetaxel—pancreatic cancer	4.47e-05	0.000406	CcSEcCtD
Carvedilol—Body temperature increased—Docetaxel—pancreatic cancer	4.47e-05	0.000406	CcSEcCtD
Carvedilol—Vision blurred—Epirubicin—pancreatic cancer	4.4e-05	0.0004	CcSEcCtD
Carvedilol—Alopecia—Doxorubicin—pancreatic cancer	4.39e-05	0.000398	CcSEcCtD
Carvedilol—Ill-defined disorder—Epirubicin—pancreatic cancer	4.33e-05	0.000393	CcSEcCtD
Carvedilol—Malnutrition—Doxorubicin—pancreatic cancer	4.32e-05	0.000392	CcSEcCtD
Carvedilol—Anaemia—Epirubicin—pancreatic cancer	4.32e-05	0.000392	CcSEcCtD
Carvedilol—Flatulence—Doxorubicin—pancreatic cancer	4.26e-05	0.000387	CcSEcCtD
Carvedilol—Tension—Doxorubicin—pancreatic cancer	4.24e-05	0.000385	CcSEcCtD
Carvedilol—Malaise—Epirubicin—pancreatic cancer	4.21e-05	0.000382	CcSEcCtD
Carvedilol—Nervousness—Doxorubicin—pancreatic cancer	4.2e-05	0.000381	CcSEcCtD
Carvedilol—Vertigo—Epirubicin—pancreatic cancer	4.2e-05	0.000381	CcSEcCtD
Carvedilol—Syncope—Epirubicin—pancreatic cancer	4.19e-05	0.00038	CcSEcCtD
Carvedilol—Leukopenia—Epirubicin—pancreatic cancer	4.18e-05	0.00038	CcSEcCtD
Carvedilol—Back pain—Doxorubicin—pancreatic cancer	4.18e-05	0.000379	CcSEcCtD
Carvedilol—Hypersensitivity—Docetaxel—pancreatic cancer	4.16e-05	0.000378	CcSEcCtD
Carvedilol—Muscle spasms—Doxorubicin—pancreatic cancer	4.15e-05	0.000377	CcSEcCtD
Carvedilol—Palpitations—Epirubicin—pancreatic cancer	4.13e-05	0.000375	CcSEcCtD
Carvedilol—Loss of consciousness—Epirubicin—pancreatic cancer	4.1e-05	0.000373	CcSEcCtD
Carvedilol—Cough—Epirubicin—pancreatic cancer	4.08e-05	0.00037	CcSEcCtD
Carvedilol—Vision blurred—Doxorubicin—pancreatic cancer	4.07e-05	0.00037	CcSEcCtD
Carvedilol—Asthenia—Docetaxel—pancreatic cancer	4.05e-05	0.000368	CcSEcCtD
Carvedilol—Convulsion—Epirubicin—pancreatic cancer	4.05e-05	0.000367	CcSEcCtD
Carvedilol—Hypertension—Epirubicin—pancreatic cancer	4.03e-05	0.000366	CcSEcCtD
Carvedilol—Ill-defined disorder—Doxorubicin—pancreatic cancer	4.01e-05	0.000364	CcSEcCtD
Carvedilol—Pruritus—Docetaxel—pancreatic cancer	4e-05	0.000363	CcSEcCtD
Carvedilol—Anaemia—Doxorubicin—pancreatic cancer	3.99e-05	0.000363	CcSEcCtD
Carvedilol—Chest pain—Epirubicin—pancreatic cancer	3.98e-05	0.000361	CcSEcCtD
Carvedilol—Myalgia—Epirubicin—pancreatic cancer	3.98e-05	0.000361	CcSEcCtD
Carvedilol—Arthralgia—Epirubicin—pancreatic cancer	3.98e-05	0.000361	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	3.95e-05	0.000358	CcSEcCtD
Carvedilol—Discomfort—Epirubicin—pancreatic cancer	3.93e-05	0.000357	CcSEcCtD
Carvedilol—Malaise—Doxorubicin—pancreatic cancer	3.9e-05	0.000354	CcSEcCtD
Carvedilol—Dry mouth—Epirubicin—pancreatic cancer	3.89e-05	0.000353	CcSEcCtD
Carvedilol—Vertigo—Doxorubicin—pancreatic cancer	3.88e-05	0.000352	CcSEcCtD
Carvedilol—Syncope—Doxorubicin—pancreatic cancer	3.87e-05	0.000352	CcSEcCtD
Carvedilol—Leukopenia—Doxorubicin—pancreatic cancer	3.87e-05	0.000351	CcSEcCtD
Carvedilol—Diarrhoea—Docetaxel—pancreatic cancer	3.87e-05	0.000351	CcSEcCtD
Carvedilol—Confusional state—Epirubicin—pancreatic cancer	3.84e-05	0.000349	CcSEcCtD
Carvedilol—Palpitations—Doxorubicin—pancreatic cancer	3.82e-05	0.000347	CcSEcCtD
Carvedilol—Oedema—Epirubicin—pancreatic cancer	3.81e-05	0.000346	CcSEcCtD
Carvedilol—Anaphylactic shock—Epirubicin—pancreatic cancer	3.81e-05	0.000346	CcSEcCtD
Carvedilol—Loss of consciousness—Doxorubicin—pancreatic cancer	3.8e-05	0.000345	CcSEcCtD
Carvedilol—Infection—Epirubicin—pancreatic cancer	3.79e-05	0.000344	CcSEcCtD
Carvedilol—Cough—Doxorubicin—pancreatic cancer	3.77e-05	0.000342	CcSEcCtD
Carvedilol—Shock—Epirubicin—pancreatic cancer	3.75e-05	0.00034	CcSEcCtD
Carvedilol—Convulsion—Doxorubicin—pancreatic cancer	3.74e-05	0.00034	CcSEcCtD
Carvedilol—Dizziness—Docetaxel—pancreatic cancer	3.74e-05	0.000339	CcSEcCtD
Carvedilol—Thrombocytopenia—Epirubicin—pancreatic cancer	3.73e-05	0.000339	CcSEcCtD
Carvedilol—Hypertension—Doxorubicin—pancreatic cancer	3.73e-05	0.000339	CcSEcCtD
Carvedilol—Tachycardia—Epirubicin—pancreatic cancer	3.72e-05	0.000338	CcSEcCtD
Carvedilol—Skin disorder—Epirubicin—pancreatic cancer	3.7e-05	0.000336	CcSEcCtD
Carvedilol—Hyperhidrosis—Epirubicin—pancreatic cancer	3.68e-05	0.000335	CcSEcCtD
Carvedilol—Myalgia—Doxorubicin—pancreatic cancer	3.68e-05	0.000334	CcSEcCtD
Carvedilol—Arthralgia—Doxorubicin—pancreatic cancer	3.68e-05	0.000334	CcSEcCtD
Carvedilol—Chest pain—Doxorubicin—pancreatic cancer	3.68e-05	0.000334	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	3.65e-05	0.000332	CcSEcCtD
Carvedilol—Discomfort—Doxorubicin—pancreatic cancer	3.63e-05	0.00033	CcSEcCtD
Carvedilol—Anorexia—Epirubicin—pancreatic cancer	3.63e-05	0.00033	CcSEcCtD
Carvedilol—Dry mouth—Doxorubicin—pancreatic cancer	3.6e-05	0.000327	CcSEcCtD
Carvedilol—Vomiting—Docetaxel—pancreatic cancer	3.59e-05	0.000326	CcSEcCtD
Carvedilol—Rash—Docetaxel—pancreatic cancer	3.56e-05	0.000323	CcSEcCtD
Carvedilol—Hypotension—Epirubicin—pancreatic cancer	3.56e-05	0.000323	CcSEcCtD
Carvedilol—Dermatitis—Docetaxel—pancreatic cancer	3.56e-05	0.000323	CcSEcCtD
Carvedilol—Confusional state—Doxorubicin—pancreatic cancer	3.56e-05	0.000323	CcSEcCtD
Carvedilol—Headache—Docetaxel—pancreatic cancer	3.54e-05	0.000321	CcSEcCtD
Carvedilol—Oedema—Doxorubicin—pancreatic cancer	3.53e-05	0.00032	CcSEcCtD
Carvedilol—Anaphylactic shock—Doxorubicin—pancreatic cancer	3.53e-05	0.00032	CcSEcCtD
Carvedilol—Infection—Doxorubicin—pancreatic cancer	3.5e-05	0.000318	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	3.47e-05	0.000315	CcSEcCtD
Carvedilol—Shock—Doxorubicin—pancreatic cancer	3.47e-05	0.000315	CcSEcCtD
Carvedilol—Thrombocytopenia—Doxorubicin—pancreatic cancer	3.45e-05	0.000313	CcSEcCtD
Carvedilol—Insomnia—Epirubicin—pancreatic cancer	3.45e-05	0.000313	CcSEcCtD
Carvedilol—Tachycardia—Doxorubicin—pancreatic cancer	3.44e-05	0.000312	CcSEcCtD
Carvedilol—Skin disorder—Doxorubicin—pancreatic cancer	3.43e-05	0.000311	CcSEcCtD
Carvedilol—Paraesthesia—Epirubicin—pancreatic cancer	3.42e-05	0.000311	CcSEcCtD
Carvedilol—Hyperhidrosis—Doxorubicin—pancreatic cancer	3.41e-05	0.00031	CcSEcCtD
Carvedilol—Dyspnoea—Epirubicin—pancreatic cancer	3.4e-05	0.000308	CcSEcCtD
Carvedilol—Somnolence—Epirubicin—pancreatic cancer	3.39e-05	0.000308	CcSEcCtD
Carvedilol—Anorexia—Doxorubicin—pancreatic cancer	3.36e-05	0.000305	CcSEcCtD
Carvedilol—Nausea—Docetaxel—pancreatic cancer	3.36e-05	0.000305	CcSEcCtD
Carvedilol—Dyspepsia—Epirubicin—pancreatic cancer	3.35e-05	0.000305	CcSEcCtD
Carvedilol—Decreased appetite—Epirubicin—pancreatic cancer	3.31e-05	0.000301	CcSEcCtD
Carvedilol—Hypotension—Doxorubicin—pancreatic cancer	3.3e-05	0.000299	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Epirubicin—pancreatic cancer	3.29e-05	0.000299	CcSEcCtD
Carvedilol—Fatigue—Epirubicin—pancreatic cancer	3.29e-05	0.000298	CcSEcCtD
Carvedilol—Pain—Epirubicin—pancreatic cancer	3.26e-05	0.000296	CcSEcCtD
Carvedilol—Constipation—Epirubicin—pancreatic cancer	3.26e-05	0.000296	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	3.21e-05	0.000292	CcSEcCtD
Carvedilol—Insomnia—Doxorubicin—pancreatic cancer	3.19e-05	0.00029	CcSEcCtD
Carvedilol—Paraesthesia—Doxorubicin—pancreatic cancer	3.17e-05	0.000287	CcSEcCtD
Carvedilol—Dyspnoea—Doxorubicin—pancreatic cancer	3.14e-05	0.000285	CcSEcCtD
Carvedilol—Feeling abnormal—Epirubicin—pancreatic cancer	3.14e-05	0.000285	CcSEcCtD
Carvedilol—Somnolence—Doxorubicin—pancreatic cancer	3.14e-05	0.000285	CcSEcCtD
Carvedilol—Gastrointestinal pain—Epirubicin—pancreatic cancer	3.12e-05	0.000283	CcSEcCtD
Carvedilol—Dyspepsia—Doxorubicin—pancreatic cancer	3.1e-05	0.000282	CcSEcCtD
Carvedilol—Decreased appetite—Doxorubicin—pancreatic cancer	3.07e-05	0.000278	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	3.04e-05	0.000276	CcSEcCtD
Carvedilol—Fatigue—Doxorubicin—pancreatic cancer	3.04e-05	0.000276	CcSEcCtD
Carvedilol—Urticaria—Epirubicin—pancreatic cancer	3.03e-05	0.000275	CcSEcCtD
Carvedilol—Constipation—Doxorubicin—pancreatic cancer	3.02e-05	0.000274	CcSEcCtD
Carvedilol—Pain—Doxorubicin—pancreatic cancer	3.02e-05	0.000274	CcSEcCtD
Carvedilol—Abdominal pain—Epirubicin—pancreatic cancer	3.01e-05	0.000274	CcSEcCtD
Carvedilol—Body temperature increased—Epirubicin—pancreatic cancer	3.01e-05	0.000274	CcSEcCtD
Carvedilol—Feeling abnormal—Doxorubicin—pancreatic cancer	2.91e-05	0.000264	CcSEcCtD
Carvedilol—Gastrointestinal pain—Doxorubicin—pancreatic cancer	2.88e-05	0.000262	CcSEcCtD
Carvedilol—Hypersensitivity—Epirubicin—pancreatic cancer	2.81e-05	0.000255	CcSEcCtD
Carvedilol—Urticaria—Doxorubicin—pancreatic cancer	2.8e-05	0.000254	CcSEcCtD
Carvedilol—Abdominal pain—Doxorubicin—pancreatic cancer	2.79e-05	0.000253	CcSEcCtD
Carvedilol—Body temperature increased—Doxorubicin—pancreatic cancer	2.79e-05	0.000253	CcSEcCtD
Carvedilol—Asthenia—Epirubicin—pancreatic cancer	2.73e-05	0.000248	CcSEcCtD
Carvedilol—Pruritus—Epirubicin—pancreatic cancer	2.7e-05	0.000245	CcSEcCtD
Carvedilol—Diarrhoea—Epirubicin—pancreatic cancer	2.61e-05	0.000237	CcSEcCtD
Carvedilol—Hypersensitivity—Doxorubicin—pancreatic cancer	2.6e-05	0.000236	CcSEcCtD
Carvedilol—Asthenia—Doxorubicin—pancreatic cancer	2.53e-05	0.00023	CcSEcCtD
Carvedilol—Dizziness—Epirubicin—pancreatic cancer	2.52e-05	0.000229	CcSEcCtD
Carvedilol—Pruritus—Doxorubicin—pancreatic cancer	2.49e-05	0.000227	CcSEcCtD
Carvedilol—Vomiting—Epirubicin—pancreatic cancer	2.42e-05	0.00022	CcSEcCtD
Carvedilol—Diarrhoea—Doxorubicin—pancreatic cancer	2.41e-05	0.000219	CcSEcCtD
Carvedilol—Rash—Epirubicin—pancreatic cancer	2.4e-05	0.000218	CcSEcCtD
Carvedilol—Dermatitis—Epirubicin—pancreatic cancer	2.4e-05	0.000218	CcSEcCtD
Carvedilol—Headache—Epirubicin—pancreatic cancer	2.39e-05	0.000217	CcSEcCtD
Carvedilol—Dizziness—Doxorubicin—pancreatic cancer	2.33e-05	0.000212	CcSEcCtD
Carvedilol—Nausea—Epirubicin—pancreatic cancer	2.26e-05	0.000206	CcSEcCtD
Carvedilol—Vomiting—Doxorubicin—pancreatic cancer	2.24e-05	0.000204	CcSEcCtD
Carvedilol—Rash—Doxorubicin—pancreatic cancer	2.22e-05	0.000202	CcSEcCtD
Carvedilol—Dermatitis—Doxorubicin—pancreatic cancer	2.22e-05	0.000202	CcSEcCtD
Carvedilol—Headache—Doxorubicin—pancreatic cancer	2.21e-05	0.000201	CcSEcCtD
Carvedilol—Nausea—Doxorubicin—pancreatic cancer	2.09e-05	0.00019	CcSEcCtD
Carvedilol—ADRA2B—Signaling Pathways—CXCL8—pancreatic cancer	1.76e-06	1.61e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—HRAS—pancreatic cancer	1.76e-06	1.61e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PTEN—pancreatic cancer	1.76e-06	1.61e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—HRAS—pancreatic cancer	1.76e-06	1.61e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CD—pancreatic cancer	1.75e-06	1.6e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—HRAS—pancreatic cancer	1.75e-06	1.6e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CXCL8—pancreatic cancer	1.74e-06	1.59e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—PIK3CA—pancreatic cancer	1.74e-06	1.59e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—HRAS—pancreatic cancer	1.73e-06	1.58e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—AKT1—pancreatic cancer	1.72e-06	1.57e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CD—pancreatic cancer	1.72e-06	1.57e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PIK3CB—pancreatic cancer	1.71e-06	1.57e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—AKT1—pancreatic cancer	1.71e-06	1.57e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—AKT1—pancreatic cancer	1.7e-06	1.56e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CASP3—pancreatic cancer	1.7e-06	1.56e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.7e-06	1.56e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CASP3—pancreatic cancer	1.69e-06	1.54e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PIK3CB—pancreatic cancer	1.69e-06	1.54e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—KRAS—pancreatic cancer	1.68e-06	1.54e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—AKT1—pancreatic cancer	1.68e-06	1.54e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CASP3—pancreatic cancer	1.67e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	1.66e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—APOE—pancreatic cancer	1.66e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCND1—pancreatic cancer	1.66e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	1.65e-06	1.51e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CD—pancreatic cancer	1.65e-06	1.51e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTGS2—pancreatic cancer	1.65e-06	1.51e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CXCL8—pancreatic cancer	1.65e-06	1.51e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCND1—pancreatic cancer	1.64e-06	1.5e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CTNNB1—pancreatic cancer	1.64e-06	1.5e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—HRAS—pancreatic cancer	1.64e-06	1.5e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—TYMS—pancreatic cancer	1.63e-06	1.5e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—SRC—pancreatic cancer	1.63e-06	1.49e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CTNNB1—pancreatic cancer	1.63e-06	1.49e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CD44—pancreatic cancer	1.63e-06	1.49e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCND1—pancreatic cancer	1.62e-06	1.48e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CXCL8—pancreatic cancer	1.62e-06	1.48e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—HRAS—pancreatic cancer	1.61e-06	1.47e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MMP9—pancreatic cancer	1.61e-06	1.47e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CTNNB1—pancreatic cancer	1.61e-06	1.47e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PTEN—pancreatic cancer	1.6e-06	1.46e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	1.6e-06	1.46e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MMP9—pancreatic cancer	1.59e-06	1.46e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—AKT1—pancreatic cancer	1.59e-06	1.46e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—VEGFA—pancreatic cancer	1.59e-06	1.45e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PTEN—pancreatic cancer	1.59e-06	1.45e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.58e-06	1.45e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CASP3—pancreatic cancer	1.58e-06	1.44e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MMP9—pancreatic cancer	1.57e-06	1.44e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—STAT3—pancreatic cancer	1.57e-06	1.44e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—APOE—pancreatic cancer	1.57e-06	1.44e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NRAS—pancreatic cancer	1.57e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—AKT1—pancreatic cancer	1.57e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PTEN—pancreatic cancer	1.56e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	1.56e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—AKT1—pancreatic cancer	1.56e-06	1.43e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GCG—pancreatic cancer	1.56e-06	1.43e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—APOE—pancreatic cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—AKT1—pancreatic cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CASP3—pancreatic cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—AKT1—pancreatic cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—AKT1—pancreatic cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—PIK3CA—pancreatic cancer	1.55e-06	1.41e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCND1—pancreatic cancer	1.53e-06	1.4e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CB—pancreatic cancer	1.53e-06	1.4e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—AKT1—pancreatic cancer	1.53e-06	1.4e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CTNNB1—pancreatic cancer	1.52e-06	1.39e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTGS2—pancreatic cancer	1.51e-06	1.39e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCND1—pancreatic cancer	1.51e-06	1.38e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CG—pancreatic cancer	1.5e-06	1.37e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	1.5e-06	1.37e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CTNNB1—pancreatic cancer	1.5e-06	1.37e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MMP9—pancreatic cancer	1.49e-06	1.36e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—SRC—pancreatic cancer	1.48e-06	1.36e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PTEN—pancreatic cancer	1.48e-06	1.36e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.47e-06	1.35e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—SRC—pancreatic cancer	1.47e-06	1.35e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MMP9—pancreatic cancer	1.47e-06	1.34e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—STK11—pancreatic cancer	1.47e-06	1.34e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MYC—pancreatic cancer	1.46e-06	1.34e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PTEN—pancreatic cancer	1.46e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TGFB1—pancreatic cancer	1.46e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—SRC—pancreatic cancer	1.45e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PPARG—pancreatic cancer	1.45e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VEGFA—pancreatic cancer	1.44e-06	1.32e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	1.44e-06	1.32e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CB—pancreatic cancer	1.44e-06	1.32e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	1.44e-06	1.32e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTEN—pancreatic cancer	1.44e-06	1.32e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	1.44e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VEGFA—pancreatic cancer	1.43e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—STAT3—pancreatic cancer	1.43e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	1.43e-06	1.31e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTGS2—pancreatic cancer	1.43e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NRAS—pancreatic cancer	1.43e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—pancreatic cancer	1.43e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—AKT1—pancreatic cancer	1.42e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—STAT3—pancreatic cancer	1.42e-06	1.3e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	1.42e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NRAS—pancreatic cancer	1.41e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VEGFA—pancreatic cancer	1.41e-06	1.29e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	1.4e-06	1.28e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—STAT3—pancreatic cancer	1.4e-06	1.28e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NRAS—pancreatic cancer	1.4e-06	1.28e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	1.39e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	1.39e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	1.38e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	1.37e-06	1.26e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PPARG—pancreatic cancer	1.37e-06	1.25e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PPARG—pancreatic cancer	1.35e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	1.35e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KRAS—pancreatic cancer	1.35e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	1.34e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	1.34e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	1.34e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MYC—pancreatic cancer	1.33e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	1.33e-06	1.22e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—APOE—pancreatic cancer	1.33e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	1.33e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TGFB1—pancreatic cancer	1.33e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	1.32e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	1.32e-06	1.21e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTEN—pancreatic cancer	1.32e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CD—pancreatic cancer	1.32e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	1.32e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	1.32e-06	1.2e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	1.31e-06	1.2e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	1.3e-06	1.19e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	1.3e-06	1.19e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MYC—pancreatic cancer	1.3e-06	1.19e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—pancreatic cancer	1.3e-06	1.19e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	1.3e-06	1.19e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TGFB1—pancreatic cancer	1.3e-06	1.19e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	1.29e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	1.29e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	1.29e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	1.28e-06	1.17e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—pancreatic cancer	1.27e-06	1.16e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	1.26e-06	1.16e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.26e-06	1.15e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.26e-06	1.15e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	1.25e-06	1.14e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PIK3CA—pancreatic cancer	1.25e-06	1.14e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	1.25e-06	1.14e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTEN—pancreatic cancer	1.25e-06	1.14e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	1.24e-06	1.14e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PIK3CA—pancreatic cancer	1.24e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	1.23e-06	1.13e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	1.23e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	1.23e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KRAS—pancreatic cancer	1.23e-06	1.12e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	1.23e-06	1.12e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	1.22e-06	1.11e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	1.21e-06	1.11e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	1.21e-06	1.11e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	1.21e-06	1.11e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	1.2e-06	1.1e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	1.2e-06	1.1e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KRAS—pancreatic cancer	1.2e-06	1.1e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	1.2e-06	1.1e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	1.2e-06	1.1e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—pancreatic cancer	1.2e-06	1.1e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	1.18e-06	1.08e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	1.17e-06	1.07e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	1.17e-06	1.07e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	1.16e-06	1.06e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PPARG—pancreatic cancer	1.16e-06	1.06e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	1.15e-06	1.06e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CB—pancreatic cancer	1.15e-06	1.05e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HRAS—pancreatic cancer	1.15e-06	1.05e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTGS2—pancreatic cancer	1.14e-06	1.04e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	1.14e-06	1.04e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PIK3CA—pancreatic cancer	1.13e-06	1.03e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	1.12e-06	1.02e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	1.12e-06	1.02e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	1.12e-06	1.02e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PIK3CA—pancreatic cancer	1.1e-06	1.01e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—pancreatic cancer	1.09e-06	9.99e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	1.09e-06	9.94e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	1.08e-06	9.93e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	1.08e-06	9.9e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	1.08e-06	9.84e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	1.08e-06	9.84e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	1.08e-06	9.84e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTGS2—pancreatic cancer	1.07e-06	9.84e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	1.07e-06	9.82e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	1.07e-06	9.82e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—pancreatic cancer	1.07e-06	9.77e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTGS2—pancreatic cancer	1.07e-06	9.75e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	1.05e-06	9.65e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	1.05e-06	9.63e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	1.04e-06	9.56e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HRAS—pancreatic cancer	1.04e-06	9.56e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	1.03e-06	9.47e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	1.03e-06	9.41e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—APOE—pancreatic cancer	1.03e-06	9.38e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HRAS—pancreatic cancer	1.02e-06	9.35e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—AKT1—pancreatic cancer	1.02e-06	9.34e-06	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—AKT1—pancreatic cancer	1.02e-06	9.32e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	1.01e-06	9.29e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—AKT1—pancreatic cancer	1.01e-06	9.26e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	1.01e-06	9.25e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	9.99e-07	9.15e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	9.97e-07	9.12e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTEN—pancreatic cancer	9.95e-07	9.1e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	9.95e-07	9.1e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	9.94e-07	9.1e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	9.78e-07	8.95e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	9.66e-07	8.84e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	9.51e-07	8.7e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTEN—pancreatic cancer	9.37e-07	8.58e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CA—pancreatic cancer	9.32e-07	8.53e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTEN—pancreatic cancer	9.29e-07	8.5e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	9.25e-07	8.47e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	9.24e-07	8.45e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—AKT1—pancreatic cancer	9.22e-07	8.44e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	9.19e-07	8.41e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	9.14e-07	8.36e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	9.13e-07	8.36e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS2—pancreatic cancer	9.1e-07	8.33e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—AKT1—pancreatic cancer	9.02e-07	8.25e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PPARG—pancreatic cancer	8.93e-07	8.17e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	8.83e-07	8.08e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CA—pancreatic cancer	8.78e-07	8.04e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	8.53e-07	7.81e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	8.48e-07	7.76e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	8.45e-07	7.73e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	8.4e-07	7.69e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—AKT1—pancreatic cancer	8.29e-07	7.59e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	8.21e-07	7.51e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	8.14e-07	7.45e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTEN—pancreatic cancer	7.94e-07	7.27e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	7.85e-07	7.18e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—AKT1—pancreatic cancer	7.61e-07	6.97e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	7.46e-07	6.83e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—AKT1—pancreatic cancer	7.18e-07	6.57e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	7.09e-07	6.49e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS2—pancreatic cancer	7.03e-07	6.43e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CA—pancreatic cancer	7.02e-07	6.42e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	6.93e-07	6.34e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	6.61e-07	6.05e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	6.55e-07	6e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTEN—pancreatic cancer	6.13e-07	5.61e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—AKT1—pancreatic cancer	5.73e-07	5.25e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	5.6e-07	5.13e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—AKT1—pancreatic cancer	5.4e-07	4.94e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—AKT1—pancreatic cancer	5.35e-07	4.9e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—AKT1—pancreatic cancer	4.58e-07	4.19e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	4.32e-07	3.96e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—AKT1—pancreatic cancer	3.53e-07	3.23e-06	CbGpPWpGaD
